Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Barr Pharmaceuticals, Inc.
Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin and Yaz Oral Contraceptives
July 12th, 2008
Barr Pharmaceuticals, Inc. (NYSE:BRL) announced that its wholly owned subsidiary, Barr Laboratories, Inc. has entered into supply and licensing agreements with Bayer for generic versions of Bayer's Yasmin(R) (drospirenone and ethinyl estradiol) and Yaz(R) (drospirenone and ethinyl estradiol) oral contraceptive products. Under terms of these agreements, Bayer will supply Barr with the generic products for launch prior to the expiration of the patents protecting these products and Barr will have sole responsibility to market, sell and distribute the products in the U.S. under the Barr Laboratories label. "We are very pleased to have reached these licensing agreements with...
Source: Law & Health Weekly (2008-07-12)
|
